Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes

Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes

Objective To evaluate the risk of serious adverse events among patients with type 2 diabetes mellitus initiating saxagliptin compared with oral antidiabetic drugs (OADs) in classes other than dipeptidyl peptidase-4 (DPP-4) inhibitors.Research design and methods Cohort studies using 2009–2014 data fr...

Full description

Saved in:
Bibliographic Details
Main Authors: Qing Liu, Sean Hennessy, Qufei Wu, K Rajender Reddy, Arlene M Gallagher, Kevin Haynes, David J Margolis, Brian L Strom, Vincent Lo Re, M Elle Saine, Craig W Newcomb, Jason A Roy, Serena Cardillo, Stephen E Kimmel, Peter P Reese, Andrea J Apter, Harshvinder Bhullar, Daina B Esposito, Dean M Carbonari
Format: Article
Language:English
Published: BMJ Publishing Group 2017-07-01
Series:BMJ Open Diabetes Research & Care
Online Access:https://drc.bmj.com/content/5/1/e000400.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://drc.bmj.com/content/5/1/e000400.full

Similar Items